肝硬化
非酒精性脂肪肝
脂肪性肝炎
肝细胞癌
疾病
脂肪肝
纤维化
医学
炎症
非酒精性脂肪性肝炎
药物发现
生物信息学
药理学
生物
内科学
作者
Haiyan Li,Ting Guan,Qin Shi,Qihao Xu,Lina Yin,Qingzhong Hu
标识
DOI:10.1016/j.drudis.2022.103471
摘要
Nonalcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) are hepatic manifestations of systemic metabolic dysfunction, which affect one-quarter of the adult population worldwide as estimated, and exhibit high risk in progressing to hepatic fibrosis, cirrhosis, and hepatocellular carcinoma. Current drug discovery focuses on modifying homeostasis of lipids, carbohydrates, and cholesterol, as well as inhibiting inflammation and fibrogenesis. Many natural products show promising activities on various molecular targets involving these mechanisms; however, they have not been fully exploited. Since some compounds are components of healthy food, they may be employed in chemoprevention as adjuvants to lifestyle modification, while natural products such as alkaloids and sesquiterpenoids could serve as promising starting points for structural modifications and deserve further development.
科研通智能强力驱动
Strongly Powered by AbleSci AI